Stock Scorer

EQL Pharma AB (EQL.ST)

EQL Pharma AB reported revenue of 432.7M SEK for the year ending 31 March 2026, up 15.8% from 373.5M a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 03-31. Amounts in SEK. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in SEK.
FigurePeriodAmountYear on year
Revenue 2026 · ending 31 March 2026 432.7M +15.8%
Gross Profit 2026 · ending 31 March 2026 162.8M +4.4%
Operating Income 2026 · ending 31 March 2026 48.7M -27.7%
Net Income 2026 · ending 31 March 2026 12.5M -70.9%
Cost of Revenue 2026 · ending 31 March 2026 269.8M +24.0%
Operating Cash Flow 2026 · ending 31 March 2026 28.4M —
Free Cash Flow 2026 · ending 31 March 2026 22.9M —
Shares Outstanding 2026 · ending 1 April 2026 29.9M -0.3%
EPS 2026 · ending 31 March 2026 0.42 -70.8%

Revenue and profit by financial year

As filed, in SEK. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20262026-03-31 432.7M48.7M12.5M22.9M
20252025-03-31 373.5M67.4M43.1M-30.8M
20242024-03-31 264.2M32.6M22.7M-12.4M

Every period

Revenue Annual

PeriodEndingRevenue
FY262026-03-31432.7M
FY252025-03-31373.5M
FY242024-03-31264.2M

Gross Profit Annual

PeriodEndingGross Profit
FY262026-03-31162.8M
FY252025-03-31156M
FY242024-03-31115M

Operating Income Annual

PeriodEndingOperating Income
FY262026-03-3148.7M
FY252025-03-3167.4M
FY242024-03-3132.6M

Net Income Annual

PeriodEndingNet Income
FY262026-03-3112.5M
FY252025-03-3143.1M
FY242024-03-3122.7M

Cost of Revenue Annual

PeriodEndingCost of Revenue
FY262026-03-31269.8M
FY252025-03-31217.6M
FY242024-03-31149.1M

Operating Cash Flow Annual

PeriodEndingOperating Cash Flow
FY262026-03-3128.4M
FY252025-03-31-24.7M
FY242024-03-31-11.4M

Free Cash Flow Annual

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
FY262026-03-3122.9M
FY252025-03-31-30.8M
FY242024-03-31-12.4M

Shares Outstanding Annual

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
FY272026-04-0129.9M
FY262025-04-0129.9M
FY252024-04-0129.9M

EPS Annual

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
FY262026-03-310.42
FY252025-03-311.44
FY242024-03-310.76